Amgen, Astra's brodalumab meets goals in Phase 3 psoriasis study

May 9, 2014 8:11 PM

17 0

May 9 (Reuters) - An antibody drug under development by Amgen Inc and AstraZeneca Plc met the goals of a Phase 3 study in patients with moderate-to-severe plaque psoriasis, the companies said on Friday.

The 661-patient trial of brodalumab met all primary and secondary endpoints for both of the evaluated doses, they said. It showed that 83 percent of patients given the highest dose, and 60 percent of patients on a lower dose, achieved at least a 75 percent reduction in disease severity after 12 week...

Read more

To category page